Cargando…

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

PURPOSE: TAS-102 is a novel oral agent combining the antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil (molar ratio 1:0.5). TAS-102 has shown good activity in refractory metastatic colorectal cancer with acceptable safety. No QT pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bendell, Johanna C., Patel, Manish R., Yoshida, Kenichiro, Seraj, Jabed, Weaver, Racquel, Lemech, Charlotte, Todaro, Thomas G., Pant, Shubham, Arkenau, Hendrik-Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882359/ https://www.ncbi.nlm.nih.gov/pubmed/27151157 http://dx.doi.org/10.1007/s00280-016-3031-9

Ejemplares similares

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
por: Lemech, Charlotte, et al.
Publicado: (2012)

Biomarkers in Advanced Colorectal Cancer: Challenges in Translating Clinical Research into Practice
por: Lemech, Charlotte, et al.
Publicado: (2011)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Difference in Neutropenia due to Administration Schedule of TAS-102
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
por: Bendell, Johanna C., et al.
Publicado: (2018)

Research Biopsies in the Context of Early Phase Oncology Studies: Clinical and Ethical Considerations
por: Saggese, Matilde, et al.
Publicado: (2013)

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
por: Laille, Eric, et al.
Publicado: (2015)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
por: Cleary, James M., et al.
Publicado: (2017)

Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
por: Chen, Duke, et al.
Publicado: (2018)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
por: Conti, Matteo, et al.
Publicado: (2023)

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations
por: Rodón, Jordi, et al.
Publicado: (2022)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT
por: Hughes, Andrew, et al.
Publicado: (2016)

Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT
por: Hughes, Andrew, et al.
Publicado: (2016)

Mammographic Breast Density and Urbanization: Interactions with BMI, Environmental, Lifestyle, and Other Patient Factors
por: Perry, Nick, et al.
Publicado: (2020)

A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
por: Piha-Paul, Sarina A., et al.
Publicado: (2021)

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
por: TANAKA, NOZOMU, et al.
Publicado: (2014)

Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine
por: Baba, Yuji, et al.
Publicado: (2017)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
por: Watanabe, Daichi, et al.
Publicado: (2023)

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
por: Bendell, Johanna C, et al.
Publicado: (2015)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases
por: Fidelman, Nicholas, et al.
Publicado: (2022)

Shieldings: TAS
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_t5d4keqa46dful1iaqe0d4s8tl